Chlorpromazine Hydrochloride is intended for the following indications:
treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Chlorpromazine Hydrochloride is intended for the following indications:
treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Schizophrenia and other psychoses (especially paranoia), mania and hypomania. In anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behavior. Is used as an adjunct in the short-term management of these conditions.
·Intractable hiccup.
·Nausea and vomiting in terminal illness (where other drugs have failed or are not available).
·Induction of hypothermia is facilitated by Chlorpromazine Tablets which prevents shivering and causes vasodilatation.
Childhood schizophrenia and autism
Aminocaproic acid is indicated for use in patients of all ages in haemorrhage caused by local or general fibrinolysis, including in Postsurgical haemorrhages in:
•Urology (surgery of the bladder and prostate)
•Gynaecology (cervical surgery), in patients where tranexamic acid is not available or not tolerated
•Obstetrics (post-partum and post-miscarriage haemorrhages) after correction of the coagulation defect
•Heart surgery (with or without bypass placement)
•Gastroenterology
•Odonto-stomatology (dental extractions in haemophiliacs, patients undergoing anticoagulanttherapy) Life-threatening haemorrhages induced by thrombolytics (streptokinase, etc.). Haemorrhages associated with thrombocytopenia, thrombopenic purpura, leukaemia. Nonsurgical haematuria of the lower urinary tract (secondary to cystitis, etc.). Intense menstruations, menorrhagia and haemorrhagic metropathies. Angioneurotic oedema.
Rupatadine Fumarate 1 mg/ml oral solution is indicated for the symptomatic treatment of:
-Allergic rhinitis (including persistent allergic rhinitis) in children aged 2 to 11 years.
-Urticaria in children aged 2 to 11 years.
Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective, sexual stimulation is required. Tadalafil is not indicated for use by women.
Mepolizumab is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype
Breast cancer
Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
• operable node-positive breast cancer
• operable node-negative breast cancer
For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1).
Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.
Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
Non-small cell lung cancer
Docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Prostate cancer
Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
Gastric adenocarcinoma
Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease
Head and neck cancer
Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
